Northera approved for rare blood pressure condition

February 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson's disease and other . Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.

Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.

Other less serious side effects could include headache, dizziness, nausea, and fatigue, the FDA said.

Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.

Explore further: Iclusig approved for rare leukemias

More information: The FDA has more about this approval.

Related Stories

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Pomalyst approved for advanced multiple myeloma

February 9, 2013

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

Adempas approved to treat pulmonary hypertension

October 9, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Opsumit approved for pulmonary arterial hypertension

October 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Vimizim approved for rare childhood disorder

February 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Recommended for you

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

FDA bolsters warnings about class of antibiotics

July 26, 2016

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.